Medication info
Sitaglutin Tablet 50 mg (Sitagliptin Hydrochloride Monohydrate)

Sitaglutin Tablet 50 mg (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tablet
Manufacturer / importer
Ilhwa Co., Ltd.
Appearance
Bright orange, double convex, round film-coated tablet
Packaging
Sitagliptin single agent - 30 tablets/box [(10 tablets/PTPX3)]
Approval status
Active

MFDS item code 202302014 · Approved 2023.06.30 · Insurance code 640904570

Summary

Main use
Improves blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medicine is administered at 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken regardless of meals. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). Patients with renal impairment Because dose adjustment according to renal function is necessary, assessment of renal function before and periodically after administration of this medicine is recommended. 1. No dose adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Ilhwa Co., Ltd.

Efficacy & effects

Improves blood glucose control in type 2 diabetes mellitus

View approved original text

This medication is used to assist patients with type 2 diabetes in managing their blood sugar levels. When taken along with dietary adjustments and exercise, it can effectively control blood sugar levels. It can be used alone or in combination with other medications, allowing for tailored treatment for individual patients. This helps stabilize blood sugar levels and prevent complications. Therefore, this medication is used for improving blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

This medicine is administered at 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken regardless of meals. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). Patients with renal impairment Because dose adjustment according to renal function is necessary, assessment of renal function before and periodically after administration of this medicine is recommended. 1. No dose adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Precautions

This medication may rarely cause severe allergic reactions; if sudden rashes, difficulty breathing, or swelling of the face and neck occur after taking the medication, discontinue use immediately and consult with a healthcare professional. There are reports of serious side effects such as pancreatitis, which is inflammation of the pancreas. If symptoms such as abdominal pain, vomiting, or severe indigestion occur during treatment, seek medical attention immediately. It is advisable not to use this medication in patients with type 1 diabetes or diabetic ketoacidosis, and it should not be administered if there is an allergy to this medication or its ingredients. Patients with impaired kidney function may experience delayed excretion of this medication, so dosage should be adjusted based on kidney function, and regular kidney function tests are important. Mild infection symptoms such as cold or headache may appear during treatment; however, severe side effects occur rarely, but if abnormal symptoms persist, notify healthcare personnel. When taken in combination with insulin or sulfonylureas, the risk of hypoglycemia may increase, so blood sugar levels should be monitored frequently, and appropriate measures should be taken if hypoglycemic symptoms occur. The safety of this medication during pregnancy has not been established, so pregnant women are advised to avoid use, and breastfeeding women are also recommended not to take this medication. Safety and efficacy have not been adequately proven in children and adolescents; therefore, use is not recommended for those under 18 years of age. Elderly patients may have decreased renal function, so regular monitoring of renal function before and after taking this medication is necessary, and dosage should be adjusted if needed. In the case of overdose, general treatment and monitoring are required, and this medication may be partially removed through hemodialysis, so dialysis treatment may be considered in cases of severe overdose. There have been no significant interactions reported between this medication and others, but caution is needed when taken in combination with cyclosporine or digoxin; inform healthcare personnel of any other medications being taken. If symptoms such as joint pain or skin blistering occur during treatment, consult a doctor immediately for appropriate testing and possibly discontinue medication.

Side effects

anaphylaxis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air exposure and kept at room temperature between 1 to 30 degrees Celsius. Proper storage helps maintain the effectiveness of the medication and prevents deterioration.

Appearance and packaging

Appearance

Bright orange, double convex, round film-coated tablet

Package unit

Sitagliptin single agent - 30 tablets/box [(10 tablets/PTPX3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.